Chemoinformaics analysis of Linalyl valerate
| Molecular Weight | 238.371 | nRot | 8 |
| Heavy Atom Molecular Weight | 212.163 | nRig | 3 |
| Exact Molecular Weight | 238.193 | nRing | 0 |
| Solubility: LogS | -4.798 | nHRing | 0 |
| Solubility: LogP | 4.668 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 43 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 17 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 26 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 43.9906 |
| nHD | 0 | BPOL | 28.6874 |
| QED | 0.462 |
| Synth | 3.214 |
| Natural Product Likeliness | 1.797 |
| NR-PPAR-gamma | 0.045 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.794 |
| Pgp-sub | 0.001 |
| HIA | 0.005 |
| CACO-2 | -4.489 |
| MDCK | 0.0000224 |
| BBB | 0.35 |
| PPB | 0.936174 |
| VDSS | 1.572 |
| FU | 0.0838562 |
| CYP1A2-inh | 0.668 |
| CYP1A2-sub | 0.173 |
| CYP2c19-inh | 0.586 |
| CYP2c19-sub | 0.874 |
| CYP2c9-inh | 0.354 |
| CYP2c9-sub | 0.567 |
| CYP2d6-inh | 0.186 |
| CYP2d6-sub | 0.083 |
| CYP3a4-inh | 0.829 |
| CYP3a4-sub | 0.275 |
| CL | 10.01 |
| T12 | 0.412 |
| hERG | 0.023 |
| Ames | 0.004 |
| ROA | 0.026 |
| SkinSen | 0.924 |
| Carcinogencity | 0.147 |
| EI | 0.815 |
| Respiratory | 0.208 |
| NR-Aromatase | 0.041 |
| Antiviral | Yes |
| Prediction | 0.790495 |